Mona Shahriari, MD, Assistant Clinical Professor of Dermatology at Yale University School of Medicine in New Haven, CT, and Associate Director of Clinical Trials at CCD Research, discusses how next-generation non-steroidal topical therapies for psoriasis including tapinarof (Vtama, Dermavant) cream, a novel, aryl hydrocarbon receptor agonist, are raising the bar, helping patients regain control of their psoriasis and their lives.
